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Randomized Controlled Crossover Trials of the
Pharmacokinetics of PRC-063, a Novel Multilayer
Extended-Release Formulation of Methylphenidate,
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Abstract:
Purpose/Background: PRC-063 is a once-daily, extended-release oral
formulation of methylphenidate hydrochloride developed to provide early
and prolonged symptom improvement in patients with attention-deficit/
hyperactivity disorder.
Methods/Procedures: We conducted 3 randomized, open-label cross-
over studies of the pharmacokinetics of PRC-063 in healthy, nonobese
men and women aged 18 to 45 years. PRC-063 (100 mg/d) was compared
with immediate-release methylphenidate (20 mg, 3 times daily) when ad-
ministered on a single day under fasted and fed conditions and at steady
state (day 5 of repeat dosing under fasted conditions). The pharmacokinet-
ics of PRC-063 administered as capsule contents sprinkled on apple sauce,
yoghurt, or ice cream were also investigated.
Findings/Results: PRC-063 demonstrated biphasic absorption, with 2
distinct peak plasma concentrations. Intake of a high-fat, high-calorie meal
did not increase the peak plasma methylphenidate concentration (Cmax) or
extent of absorption (area under the curve), however; it resulted in slower
uptake versus a fasted state. During repeated dosing, steady state was
reached with no further accumulation of methylphenidate from day 3. At
steady state, PRC-063 gave higher evening and trough plasma methylphe-
nidate levels than immediate-release methylphenidate (3 times daily). The
pharmacokinetics of PRC-063 sprinkled on food were comparable to that
of intact capsules. Reported adverse events (AEs) were consistent with the
established safety profile of methylphenidate. There were no serious AEs,
but 3 subjects discontinued the repeat-dosing study because of AEs
assessed as possibly related to study treatment.
Implications/Conclusions: Our data indicate that PRC-063 can be
taken with or without food or by sprinkling capsule contents on food.
Key Words: Adhansia, FOQUEST, methylphenidate, pharmacokinetics,
ADHD
(J Clin Psychopharmacol 2020;40: 579–587)
A ttention-deficit/hyperactivity disorder (ADHD) causes im-paired functioning, which can manifest as poor school or
work performance.1 Attention-deficit/hyperactivity disorder im-
pairments can extend from wakening until bedtime, affecting ac-
tivities before and after school and work. For this reason, some
patients may require a medication that, when taken in the morn-
ing, provides rapid and daylong symptommanagement.2 A rapid
onset of action means that patients do not need to wake earlier
than usual to take their medication or take a medication the night
before to achieve a morning effect,3 whereas a long duration
of action means that patients may not need to supplement with
short-acting medications later in the day. A rapid onset may also
have practical advantages, perhaps helping parents to get their
children to school or themselves to work.
Since being established as standard treatments for ADHD,
stimulants such as methylphenidate and mixed amphetamine salts
have evolved from immediate-release (IR) medications administered
as multiple daily doses to longer-acting formulations designed for
once-daily dosing.4,5 Multiple dosing is associated with rebound
and wear-off affecting the end of the day, quality of life issues relat-
ing to privacy and stigmatization, and problems with treatment
adherence.6–8 Moreover, although use of IR stimulants permits flex-
ibility of time of administration, this flexibility may contribute to a
lifestyle of “disorganization and procrastination.”9 Long-acting stim-
ulants promote a more consistent lifestyle, enhance planning and fa-
cilitation of an organized day, and decrease the need for “as needed”
IR doses.9 Other potential advantages of longer-acting formulations
include less fluctuation in the pharmacokinetic (PK) profile, a sim-
plified treatment regimen, and improved treatment adherence.8
Certain formulations of methylphenidate and mixed amphetamine
salts have a sufficient duration of action for once-daily dosing.10–12
However, most currently available long-acting stimulants show
evidence of diminished efficacy toward the end of the work or
school day.13 If a long-acting stimulant fails to provide a sufficient
duration of action, additional IR or long-acting stimulant doses
are often needed in the afternoon hours to extend the duration of
medication coverage.14–18
To maintain efficacy toward the end of the day, additional,
longer-acting stimulant options are needed. PRC-063 (marketed
as Adhansia XR [Purdue Pharmaceuticals L.P., Wilson, North
Carolina] in the United States and as FOQUEST [Purdue
Pharma, Pickering, Ontario] in Canada) is a once-daily, extended-
release, racemic d- and l-methylphenidate hydrochloride capsule
formulation (with d-methylphenidate being the more active
enantiomer). In the United States and Canada, it is used to
treat ADHD in patients 6 years and older. PRC-063 capsules
contain identical beads, each of which has an IR layer
containing approximately 20% of the methylphenidate dose
and a polymer-coated controlled-release (CR) layer containing
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approximately 80% of the methylphenidate dose. Dissolution of
the IR layer begins immediately upon ingestion. Release of
methylphenidate from the CR layer is delayed and occurs after
the beads have passed through the stomach. At a pH of 7 or greater,
the delayed-release polymer coating dissolves and methylphenidate
in the CR layer diffuses into the gastrointestinal tract and is absorbed.
Because of this pH-dependent release, the US Food and Drug
Administration–approved full prescribing information for PRC-06319
recommends that patients who are concomitantly taking gastric
pH modifiers be monitored for changes in clinical effects.
The safety and efficacy of PRC-063 were previously inves-
tigated in a double-blind, randomized, placebo-controlled, cross-
over workplace environment study in adult patients with ADHD
(NCT02225639), conducted at 2 sites in the United States in 2014
to 2015.20 In addition, a randomized, double-blind, parallel-group,
placebo-controlled, phase 3 adult laboratory classroom study was
completed after approval to evaluate the safety and efficacy in
adult patients with ADHD (NCT03618030).21 Patients in both
studies showed improved attention, assessed by Permanent Product
Measure of Performance total score, averaged from 1 to 16 hours
after PRC-063 dosing.20,21 In addition, mean Swanson, Kotkin,
Agler, M-Flynn, and Pelham combined score was improved during
PRC-063 treatment compared with placebo treatment.20 A similar
improvement in the Swanson, Kotkin, Agler, M-Flynn, and Pelham
combined score was observed in a 13-hour classroom trial of
PRC-063 versus placebo in children aged 6 to 12 years with
ADHD (NCT03172481).22
The efficacy and safety of PRC-063 were also evaluated in
adults with ADHD in a 4-week, randomized, double-blind, multi-
center, placebo-controlled study (NCT02139124). Compared with
placebo, PRC-063 demonstrated significantly greater improve-
ments in ADHD Rating Scale 5 total score.23 Similar efficacy re-
sults were obtained in children aged 12 to 17 years with ADHD
(NCT02139111: unpublished data). In the adult study, similar pro-
portions of PRC-063–treated and placebo-treated adult ADHD pa-
tients discontinued treatment because of adverse reactions.23
A series of phase 1 bioavailability studies were conducted to
compare the rate and extent of absorption of PRC-063 and 3 times
daily (TID) IR methylphenidate (Ritalin) under fasted and fed con-
ditions when administered on a single day (study I) and at steady
state on day 5 of repeat dosing under fasted conditions (study II),
and to determine whether the PK of PRC-063 is altered when its
capsule contents are administered by sprinkling on food rather than
as intact capsules swallowed whole (study III). The aim of this arti-
cle is to describe the PKof PRC-063, which provide the foundation
for its clinical efficacy.
MATERIALS AND METHODS
Study Overview
Three independent, phase 1 bioavailability studies were per-
formed at a single clinical facility operated by the contract re-
search organization inVentiv Health Clinical Inc (Québec City,
Québec, Canada) between October and November 2013. For each
study, the protocol and informed consent form were reviewed and
approved by an independent institutional review board (IRB Ser-
vices, Aurora, Ontario, Canada), and a no objection letter was re-
ceived from the Canadian authorities before the start of the study.
Subjects provided written informed consent before any study pro-
cedures were started. All studies were conducted in accordance
with International Council for Harmonisation Good Clinical Prac-
tices and Good Laboratory Practices, local regulatory require-
ments, and the most recent version of the Declaration of Helsinki.
Participants
Eligible participants in all studies were healthy men and
women aged 18 to 45 years with a body mass index between
18.5 and 30.0 kg/m2. Smokers who smoked 25 or fewer cigarettes
per day were eligible (smokers who smoked more than this were
excluded because of the risk of cardiovascular and other health
complications). To be eligible, women of childbearing potential
who were sexually active were required to use an effective form
of contraception throughout the study and for 30 days after the last
dose of study drug.
Exclusion criteria included the following: any clinically sig-
nificant abnormality, abnormal laboratory test result, or positive
test for hepatitis B, hepatitis C, or HIVat screening; positive drug
test result at screening, history of significant alcohol or drug
abuse, recent use of recreational drugs, or recent regular use of al-
cohol; history of allergic reactions to methylphenidate or a related
drug; use of any drug known to induce or inhibit hepatic drug me-
tabolism within 30 days before the first dose of study drug; current
pregnancy or breastfeeding; any clinically significant electrocardio-
gram abnormality or vital sign abnormality; use of an investiga-
tional drug within 30 days (90 days for biologics) of the first dose
of study drug or participation in another investigational study
within 30 days; and recent use of any medication other than a top-
ical product without significant systemic absorption or a hor-
monal contraceptive.
To eliminate typical drug interactions and ensure a consistent
release and absorption profile, subjects were required to abstain
from the following as indicated until after collection of the last
PK blood sample for the dosing period: foods and beverages con-
taining poppy seeds (from 24 hours before each dosing period);
energy drinks and foods or beverages containing xanthine deriva-
tives or xanthine-related compounds (from 48 hours before each
dosing period); food supplements and herbal supplements (from
7 days before each dosing period); food and beverages containing
grapefruit, starfruit, pomegranate, pineapple, or pomelo (from
7 days before each dosing period); recreational drugs; and alcohol
(from 24 hours before each dosing period). They were also required
not to do vigorous physical activity while at the clinical facility.
Study Design
The 3 studies were randomized, open-label studies that inves-
tigated PRC-063 (Purdue Pharma, Ontario, Canada).
Study I was a 4-way crossover study that investigated a single
dose of PRC-063 100 mg versus TID IR methylphenidate 60 mg
(20 mg at 0, 4, and 8 hours) under fasted and fed conditions to
stress the absorption and tolerability of the product. For
PRC-063, 100 mg was predicted to be the highest dose based on
PK data from pilot studies and is the highest dose available to pre-
scribers in Canada24; for IR methylphenidate, 60 mg is the highest
manufacturer-recommended daily dose.25 PRC-063 was admin-
istered either after an overnight fast of at least 10 hours, or
30 minutes after subjects started to eat a standard very high-
fat, high-calorie breakfast (800–1000 calories, with ~50% of
the total caloric content derived from fat) as 45 + 55 mg capsules
(the 100-mg capsule was not available at the time the studies
were conducted). Subjects were fasted for at least 4 hours after
PRC-063 dosing. For IR methylphenidate under fasted condi-
tions, the first daily dose was administered after an overnight fast
of at least 10 hours; the second and third daily doses were admin-
istered after a fasting period of at least 2 hours; dosing was
followed by a fasting period of at least 1.5 hours (first and second
doses) or 2 hours (third dose). For IR methylphenidate under fed
conditions, the first daily dose was administered 30 minutes after
subjects started to eat a standard high-fat, high-calorie breakfast;
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the second and third daily doses were administered 30 minutes af-
ter subjects started to eat lunch (second dose) or dinner (third
dose); and dosing was followed by a fasting period of 3.5 hours
(first and second doses) or 2 hours (third dose). PRC-063 and
IR methylphenidate were each administered on 2 separate days,
with a washout period of at least 7 days between doses. During
each dosing period, subjects were confined to the clinical facility
from at least 11 hours before the start of dosing until after the last
blood sample had been obtained. For all treatment groups, sub-
jects were required to abstain from smoking from 2 hours before
dosing until 8 hours after the first dosing to prevent any potential
interaction with absorption of methylphenidate.
Study II was a 2-way crossover study that investigated
PRC-063 100 mg (45 + 55 mg capsules), once daily versus IR
methylphenidate 20 mg, TID (at 0, 4, and 8 hours) after an over-
night fast of at least 10 hours on 5 consecutive days. For
PRC-063, subjects were fasted for at least 1.5 hours after dosing
on days 1 to 4 and for at least 4 hours after dosing on day 5. For
IRmethylphenidate, dosing on all days (including fasting periods)
was the same as dosing under fasted conditions in study I. During
each dosing period, subjects were confined to the clinical facility
from at least 10 hours before the start of dosing until after the last
blood sample had been obtained. There was a washout period of
8 days between 5-day dosing periods. Subjects were required to
abstain from smoking from 2 hours before dosing on day 5 until
8 hours after the first daily dose.
Study III was a 4-way crossover study that investigated a sin-
gle dose of PRC-063 100mg (45 + 55 mg capsules), administered
after an overnight fast of at least 10 hours either as intact capsules
or as capsule contents sprinkled on 1 tablespoon (15 mL) of un-
sweetened apple sauce, ice cream, or yoghurt. The food with the
sprinkled contents was consumed 10 minutes (±5 minutes) after
sprinkling. Subjects were fasted for at least 4 hours after dosing.
During each dosing period, subjects were confined to the clinical
facility from at least 10 hours before the start of dosing until after
the last blood sample had been obtained. There was a washout pe-
riod of 7 days between administrations. Subjects were required to
abstain from smoking from 2 hours before dosing until 6 hours af-
ter dosing.
Blood Sampling and Analysis
In study I, blood samples were obtained at the following time
points in each dosing period: before the morning PRC-063 or IR
methylphenidate dose, every half hour for the first 15 hours after
the morning dose, and at 16, 18, and 24 hours after the morning
dose. In study II, blood samples were obtained before the morning
PRC-063 or IR methylphenidate dose on days 1, 3, 4, and 5. On
day 5, additional blood samples were obtained every half hour
for the first 15 hours after morning dosing and at 16, 18, 24, 30,
and 36 hours after morning dosing. In study III, blood samples
were obtained in each dosing period before PRC-063 dosing, ev-
ery half hour for the first 8 hours after PRC-063 dosing, and at 10,
12, 14, 16, 24, 30, and 36 hours after PRC-063 dosing. In all 3
studies, actual times of blood sampling were recorded and were
used in the statistical analyses.
Blood samples (3 mL at each time point) were drawn into K2-
EDTA–coated collection tubes, cooled in an ice bath, and (within
2 hours of collection) were centrifuged at 4°C at 3000 rpm
(1999g) for 10 minutes. Plasma isolated in this way was transferred
to polypropylene tubes containing stabilization buffer (10% w/v
Na2-EDTA, 10% w/v citric acid 10%), vortexed for approximately
10 seconds, and stored in a −80°C freezer before measurement of
d- and l-methylphenidate at the same clinical facility where the
bioavailability studies were performed.
d- and l-methylphenidate levels were measured by high-
performance liquid chromatography with detection by tandem
mass spectrometry. An internal standard (methylphenidate-d9)
was added to each sample. d-methylphenidate, l-methylphenidate,
and methylphenidate-d9 were extracted from a 0.2-mL aliquot of
acidified plasma by liquid-liquid extraction with ethyl acetate/
hexane (after the addition of an alkaline solution to shift the pH
to basic) according to a proprietary method. The extracted samples
were then injected into a liquid chromatograph equipped with a
Chirobiotic V column (150 mm 4.6 mm, 5 μm; Astec, Oakville,
Canada). Mobile phase Awas a mixture of methanol, acetic acid,
and ammonium hydroxide; mobile phase B was 100% methanol.
Isocratic chromatographic chiral separation was performed at room
temperature at a flow rate of 1.5mL/min for pump 1 and of 1mL/min
for pump2.Detectionwas performedwith anAPI 5000 tandemmass
spectrometer (AB Sciex Concord, Canada) using the following set-
tings: auxiliary gas pressure, 70 psi; nebulizer gas pressure, 60 psi;
curtain gas pressure, 50 psi; TurboIonSpray temperature, 350°C;
and ion spray voltage, 3000 V. Calibration standards were used to
generate a calibration curve from which sample methylphenidate
concentrations (normalized to the internal standard) were derived.
Blank samples and quality control samples (450, 2250, 15,000, and
22,500 pg/mL for d-methylphenidate; 12, 60, 400, and 600 pg/mL
for l-methylphenidate) were also analyzed. The mass transitions
quantified were 235.3 to 84.1 amu for d-methylphenidate, 234.2
to 84.1 amu for l-methylphenidate, and 243.3 to 93.1 amu for
methylphenidate-d9. The validated quantification range for the
assay was 150 to 30,000 pg/mL for d-methylphenidate and 4 to
800 pg/mL for l-methylphenidate. Values below the lower limit
of quantification were entered as zero values in the PK analyses.
Within-day variability values, measured as the coefficient of var-
iation (CV), were 0.83% to 3.32% for d-methylphenidate and
1.38% to 14.09% for l-methylphenidate. Between-day variability
values (CV) were 3.42% to 6.69% for d-methylphenidate and
5.83% to 18.05% for l-methylphenidate.
PK Analyses
In noncompartmental PK analyses, the elimination rate con-
stant (Kel) was calculated as the slope −1 for regression analyses
of natural logarithm (ln)-transformed methylphenidate concentra-
tion versus time; the elimination half-life (T½ el) was calculated as
ln(2)/Kel; area under the plasma concentration versus time curve
from time 0 to the last measured concentration (AUC0–t) and to
24 hours (AUC0–24) was calculated by the trapezoid rule;
AUC between time 0 and infinity (AUC0–inf) was calculated
as AUC0–t + (Ct/Kel); and residual area (in percent) was calcu-
lated as (1 − (AUC0–t/AUC0–inf))  100. Maximum plasma
concentration (Cmax, Cmax0–4, Cmax8–16) and time to maximum
plasma concentration (Tmax, Tmax0–4, Tmax8–16) were also calcu-
lated. In study II, Cmin (minimum concentration at steady state)
and fluctuation index (peak-trough fluctuation at steady state:
100  (Cmax − Cmin)/Cav [where Cav = AUC0−τ/τ and
τ = 24 hours]) were also calculated.
Presented data are for d- plus l-methylphenidate (total methyl-
phenidate). In all 3 studies, d-methylphenidate accounted for more
than 97.5% of the value of AUC0–t for d- plus l-methylphenidate for
each treatment/set of treatment conditions (data not shown). Higher
oral bioavailability of d- versus l-methylphenidate has been docu-
mented previously.26,27
Statistical Analyses
Data from subjects who completed at least 2 dosing periods
(studies I and III) or from subjects who completed the study (study
II) were used in the PK analyses. In study III, one of the completed
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dosing periods was required to be dosing with intact capsules. In
all studies, subjects included in the PK analyses were required to
have an adequately characterized PK profile. Pharmacokinetic and
statistical analyses were performed using Pharsight Knowledgebase
Server version 4.0.2 and WinNonlin 5.3 or 6.4. SAS version 9.2
was used to calculate number of observations (N), mean, SD, CV
(in percent), minimum, maximum, and median for plasma con-
centrations of d- plus l-methylphenidate for each treatment/set
of treatment conditions and time point, and was also used to cal-
culate each of the PK parameters listed previously.
Treatmentswere compared by analysis of variance (ANOVA)
using the general linear models procedure in SAS on ln-
transformed data (for Cmax and AUC parameters) or untrans-
formed data (Tmax). The models included sequence, subject
within sequence, period, and treatment. Because the daily dose
was lower for IR methylphenidate than for PRC-063, additional
models were created for studies I and II using data that had been
dose normalized to 100 mg. A P value of <0.05 was considered
statistically significant.
Based on least-squares (LS) means from ANOVA of ln-
transformed data, the ratio of LS means, and corresponding 90%
geometric confidence intervals were calculated for Cmax, Cmin,
AUC0–t, AUC0–24, and AUC0–inf. Intersubject and intrasubject CVs
were also calculated. In study II, steady state was determined using
the general linear models procedure in SAS by repeated-measures
ANOVA of ln-transformed predose plasma methylphenidate con-
centrations on days 3, 4, and 5.
Safety
In all 3 studies, analysis of safety was based on all subjects
who received at least 1 dose of study medication (the safety pop-
ulation). Throughout each study, subjects were monitored for ad-
verse events (AEs) by being asked about the onset of any new
health problems and worsening of existing health problems.
Treatment-emergent AEs were coded using MedDRA, version
16.1. Adverse events were assessed for seriousness and relation-
ship to study treatment and were graded according to severity.
Study discontinuation due to AEs was recorded.
RESULTS
Baseline Characteristics and Disposition
In all 3 studies, most subjects (83%–100%) were white and
more than half were male (Supplemental Table 1 http://links.
lww.com/JCP/A690).
In study I, 30 healthy adult subjects were randomized and
dosed, of whom 24 completed all study periods. Five subjects
permanently discontinued the study because of withdrawal of
consent (2 subjects), inability to draw more blood (2 subjects),
or a positive drug test (1 subject). One subject temporarily
withdrew consent before returning to complete the remainder
of the study.
In study II, 21 healthy adult subjects were randomized and
dosed. Six subjects failed to complete the study. Reasons for
noncompletion were withdrawal of consent (3 subjects) and sig-
nificant AEs (3 subjects).
Of the 30 healthy adult subjects randomized and dosed in
study III, 26 completed all study periods. Three subjects per-
manently discontinued the study because of withdrawal of con-
sent (2 subjects) or a positive alcohol breath test (1 subject).
One subject was temporarily withdrawn from the study because
of intake of study medication in a way that contravened the
study protocol.
Pharmacokinetics
PRC-063 Versus TID IR Methylphenidate: 1-Day
Dosing Under Fed and Fasted Conditions (Study I)
Study I compared the PK of 100 mg of PRC-063 versus TID
IR methylphenidate 60 mg after an overnight fast of at least
10 hours or after a high-fat, high-calorie breakfast. Figure 1 shows
concentration versus time curves for plasma methylphenidate for
PRC-063 and TID IR methylphenidate. There are 3 clear peaks
for the 3 IR methylphenidate doses and 2 peaks for the outer and
inner methylphenidate layers of PRC-063, indicating a biphasic ab-
sorption profile. Median 0- to 4-hour Tmax was 30 minutes sooner
for PRC-063 than for the first IR methylphenidate dose under
fasting conditions and 1 hour later under fed conditions. Plasma
methylphenidate levels were higher with PRC-063 than with TID
IR methylphenidate from approximately 13–14 to 24 hours under
fed and fasted conditions. The curves for PRC-063 indicate similar
overall exposure to methylphenidate in a fed versus fasted state, but
slower uptake in a fed state. Median Tmax was 1 hour less when
PRC-063 was administered in a fasted versus fed state (Table 1).
Mean Cmax was 19% higher for fasted than for fed administration
(13.36 vs 11.26 ng/mL). Otherwise, the PK of PRC-063 were gen-
erally similar in fed and fasted states. The LS mean ratios for
PRC-063 administered in a fed versus fasted state were 97.45%
for AUC0–t, 101.87% for AUC0–inf, and 87.49% for Cmax (Supple-
mental Table 2, http://links.lww.com/JCP/A690 which shows LS
mean ratios for plasmamethylphenidate for 1-day dosing). For both
PRC-063 and IR methylphenidate, levels of methylphenidate up-
take varied considerably between individuals (Fig. 1, Table 1).
There were some notable differences in mean values for PK
parameters between PRC-063 and IR methylphenidate (Table 1).
Mean residual areawas higher for PRC-063 than for IRmethylphe-
nidate (17.21% vs 2.41% for fasted state, 18.41% vs 2.43% for fed
state). Cmax was lower for PRC-063 than for IR methylphenidate.
Ratios for AUC0–t, AUC0–inf, and Cmax for PRC-063 versus
IR methylphenidate also showed differences (Supplemental Table
2 http://links.lww.com/JCP/A690). For AUC0–t, AUC0–inf, and
Cmax, the dose-normalized ratios for 100 mg PRC-063 versus
60 mg IR methylphenidate were 75.56%, 89.75%, and 53.73%,
respectively, for administration in a fasted state and 62.04%,
77.26%, and 42.82%, respectively, for administration in a fed
state. The non–dose-normalized ratios for AUC0–t, AUC0–inf,
and Cmax for PRC-063 versus IR methylphenidate were 125.94%,
149.58%, and 89.55%, respectively, for administration in a fasted
state and 103.40%, 128.77%, and 71.36%, respectively, for admin-
istration in a fed state.
PRC-063 Versus IR Methylphenidate: 5-Day Dosing
(Study II)
Study II compared the PK of daily doses of 100 mg of
PRC-063 versus 60 mg of IR methylphenidate during 5 days
of dosing. Figure 2 shows concentration versus time curves for
plasma methylphenidate for PRC-063 and IR methylphenidate
at steady state. No statistically significant time or time  treat-
ment effect was observed in repeated-measures ANOVA of
ln-transformed predose plasma methylphenidate concentrations,
indicating that steady state was reached for both PRC-063 and
IR methylphenidate. For PRC-063, most subjects reached steady
state by day 3 (with no further accumulation of methylphenidate
after this point). At steady state, the residual plasma level of
methylphenidate 24 hours after dosing was higher for PRC-063
than for IR methylphenidate.
Table 2 shows calculated PK parameters for PRC-063 and IR
methylphenidate on day 5 of the 5-day dosing schedule. Mean
Katzman et al Journal of Clinical Psychopharmacology • Volume 40, Number 6, November/December 2020
582 www.psychopharmacology.com © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
values for AUC0–24 and AUC0–twere higher for PRC-063 than for
IR methylphenidate. Mean Cmin was higher for PRC-063 than for
IR methylphenidate (3.27 vs 0.86 ng/mL). Fluctuation index was
lower for PRC-063 than for IR methylphenidate (138.42% vs
244.02%). Cmax was similar for PRC-063 versus IR methylpheni-
date. However, when doses were normalized, Cmax was lower for
PRC-063 than for IR methylphenidate (ratio, 60.25%; Supple-
mental Table 3, http://links.lww.com/JCP/A690 which shows LS
mean ratios for plasma methylphenidate on day 5 of a 5-day dos-
ing schedule).
PRC-063 Administered as Intact Capsules Versus
Capsule Contents (Study III)
Study III compared the PKof 100mg of PRC-063 administered
as intact capsules or as capsule contents sprinkled on unsweetened
apple sauce, ice cream, or yoghurt. Figure 3 shows concentration ver-
sus time curves for plasmamethylphenidate. The curves show no no-
table differences between capsules swallowed whole and capsule
contents sprinkled on different foods.
Table 3 shows calculated PK parameters for intact capsules
and capsule contents sprinkled on food. Values for AUC parame-
ters, Cmax, and residual area were similar for intact capsules and
capsule contents sprinkled on different foods.
For AUC0–t, AUC0–inf, andCmax, LS mean ratios were calcu-
lated for capsule contents sprinkled on apple sauce, yoghurt, or ice
cream versus intact capsules (Supplemental Table 4 http://links.
lww.com/JCP/A690). For AUC0–t, AUC0–inf, andCmax, the LSmean
ratios ranged from 98% to 108% for apple sauce, 99% to 100%
for yoghurt, and 101% to 106% for ice cream, indicating minimal
differences in overall PK according to method of administration.
FIGURE 1. Concentration versus time curves for plasma d- plus l-methylphenidate after administration of PRC-063 and IRmethylphenidate in
fed and fasted states (study I). Data are shown as the mean.
TABLE 1. PK Parameters for Plasma d- Plus l-methylphenidate After Administration of PRC-063 and IR Methylphenidate in Fed and
Fasted States (Study I)
PRC-063 (100 mg) IR Methylphenidate (20 mg TID)
Fasted (n = 27) Fed (n = 27) Fasted (n = 28) Fed (n = 28)
AUC0–t*, ng · h/mL, mean ± SD (CV) 171.63 ± 47.98 (27.95%) 163.93 ± 41.43 (25.27%) 133.67 ± 44.62 (33.38%) 156.65 ± 38.54 (24.60%)
AUC0–inf, ng · h/mL, mean ± SD (CV) 209.20 ± 63.24 (30.23%) 206.00 ± 59.48 (28.87%) 137.15 ± 46.57 (33.95%) 160.73 ± 40.45 (25.17%)
Cmax, ng/mL, mean ± SD (CV) 13.36 ± 4.79 (35.88%) 11.26 ± 2.82 (25.01%) 14.21 ± 3.86 (27.18%) 15.40 ± 3.38 (21.93%)
Cmax0–4, ng/mL, mean ± SD (CV) 9.45 ± 3.28 (34.77%) 9.35 ± 1.94 (20.79%) 9.29 ± 3.47 (37.41%) 11.18 ± 3.48 (31.11%)
Cmax8–16, ng/mL, mean ± SD (CV) 12.91 ± 4.76 (36.90%) 10.93 ± 3.07 (28.10%) 13.74 ± 3.75 (27.33%) 14.29 ± 3.22 (22.54%)
Tmax, median (range), h 11.5 (1.0–16.0) 12.5 (2.5–24.0) 9.5 (2.0–11.0) 6.0 (2.1–10.5)
Tmax0–4, median (range), h 1.5 (1.0–2.5) 3.0 (1.5–4.0) 2.0 (1.0–3.0) 2.0 (1.0–4.0)
Tmax8–16, median (range), h 12.5 (8.5–16.0) 13.5 (10.5–16.0) 9.52 (9.0–11.0) 10.0 (9.0–11.5)
T½ el, mean ± SD, h 6.83 ± 3.19 6.94 ± 2.22 3.56 ± 0.40 3.56 ± 0.45
Residual area†, mean ± SD, % 17.21 ± 10.75 18.41 ± 8.49 2.41 ± 0.96 2.43 ± 0.91
*t = 24 hours.
†Twenty-four hours to infinity.
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The intrasubject CVs were 18.16% for Cmax, 8.15% for AUC0–t,
and 8.04% for AUC0–inf. Intersubject CV values indicate substan-
tial between-subject variation in the PK of PRC-063.
Safety
All randomized subjects were evaluated for safety. Across
the 3 studies, there were no serious AEs (Supplemental Table 5
http://links.lww.com/JCP/A690). All AEs were mild or moderate.
Three AEs in study II led to studywithdrawal: dizziness and blood
pressure increased during IR methylphenidate treatment, and heart
rate increased during PRC-063 treatment (1 subject each). All 3 of
these AEs were assessed as possibly related to study medication.
No AEs in study I or study III led to study withdrawal.
Across studies, the most commonAEwith PRC-063was initial
insomnia, reported by 23 subjects (30%). Headache was reported by
18 subjects treated with PRC-063 (23%), dry mouth by 12 subjects
(16%), and heart rate increased by 12 subjects (16%). The overall
rates of insomnia-related AEs (insomnia plus initial insomnia) were
39% for PRC-063 and 12% for IR methylphenidate.
Other AEs that were frequent with PRC-063 in individual
studies included agitation (23% in study III), palpitations (20%
in study III), decreased appetite (18% in study I), and insomnia
(18% in study I; Supplemental Table 5 http://links.lww.com/
JCP/A690).
DISCUSSION
In 3 phase 1 PK studies, PRC-063 was shown to have a PK
profile consistent with expectations based on the beaded formula-
tion design.
In study I, the bioavailability of PRC-063 was generally simi-
lar when it was taken in a fasted state or after a high-fat, high-calorie
meal. However, slower uptake in the fed state suggests that some
patients may benefit from taking PRC-063 immediately on waking
(rather than after a high-fat breakfast). Whether before or after
FIGURE2. Concentration versus time curves for plasmad- plus l-methylphenidate at steady state (day 5 of a 5-day dosing period) for PRC-063
and IR methylphenidate (study II). Data are shown as the mean.
TABLE 2. PK Parameters for Plasma d- Plus l-methylphenidate on Day 5 of a 5-day Dosing Schedule: PRC-063 and IR
Methylphenidate (Study II)
PRC-063 (100 mg; n = 15) IR Methylphenidate (20 mg TID; n = 15)
AUC0–24, ng · h/mL, mean ± SD (CV) 230.86 ± 87.88 (38.07%) 153.81 ± 54.50 (35.44%)
AUC0–t*, ng · h/mL, mean ± SD (CV) 253.83 ± 105.07 (41.39%) 156.60 ± 58.13 (37.12%)
Cmax, ng/mL, mean ± SD (CV) 16.14 ± 5.03 (31.15%) 16.19 ± 5.55 (34.26%)
Cmax0–4, ng/mL, mean ± SD (CV) 12.63 ± 3.81 (30.16%) 10.35 ± 2.69 (25.99%)
Cmax8–16, ng/mL, mean ± SD (CV) 15.89 ± 5.11 (32.17%) 15.67 ± 5.69 (36.31%)
Cmin, ng/mL, mean ± SD (CV)
† 3.27 ± 2.21 (67.55%) 0.86 ± 0.62 (71.92%)
Tmax, median (range), h 11.5 (2.0–16.0) 9.5 (5.0–11.0)
Tmax0–4, median (range), h 1.5 (1.0–2.5) 2.0 (1.5–2.5)
Tmax8–16, median (range), h 12.0 (8.5–16.0) 9.5 (9.0–11.0)
Fluctuation index, %, mean ± SD (CV)† 138.42 ± 29.75 (21.49%) 244.02 ± 33.64 (13.79%)
*t = 36 hours.
†n = 14 (1 subject was excluded from calculation of summary statistics because no 24-hour sample was collected for the PRC-063 arm).
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breakfast, taking PRC-063 in a consistent manner may avoid day-
to-day variability in drug uptake and onset of action.
As shown in study I, PRC-063 provides biphasic release of
methylphenidate, with the initial plasma methylphenidate peak
modeling the peak for the first IR methylphenidate dose. In fact,
median 0- to 4-hour Tmax was 30minutes earlier for PRC-063 than
for the first dose of IR methylphenidate under fasted conditions,
corroborating that the IR component of the delivery system pro-
vides the early onset of clinical effect observed within 1 hour after
administration.20,21 The subsequent dip in plasma methylpheni-
date does not seem to diminish the clinical efficacy of PRC-063,
as indicated by continued efficacy in workplace environment/
laboratory classroom studies.20,21 It is also important to note that
residual area and plasma methylphenidate concentrations at
24 hours in study I were considerably higher after a single dose
of PRC-063 than 3 doses (20 mg TID) of IR methylphenidate.
However, repeat dosing in study II showed no further accu-
mulation of methylphenidate after steady state was reached at
day 3, and fluctuation index was lower for PRC-063 than for
IR methylphenidate (138.42% vs 244.02%). In a separate analy-
sis, PK modeling showed no further accumulation of methylphe-
nidate levels when daily intake of PRC-063 was modeled out to
14 days (unpublished data). In some patients with ADHD who
require prolonged symptom improvement, there is a clinical
need for long-lasting plasma methylphenidate concentrations and
a consistent clinical effect, which the lower fluctuation index of
PRC-063 may help to achieve. Our PK findings provide the basis
for understanding the clinical effects of PRC-063 that have been
demonstrated in other studies in patients with ADHD, including a
1-hour onset of action and a duration of clinical effect of up to
16 hours.20,21 The gradual decline in plasma methylphenidate levels
and higher residual methylphenidate levels with PRC-063 versus IR
FIGURE 3. Concentration versus time curves for plasma d- plus l-methylphenidate after administration of PRC-063 as intact capsules or
sprinkled on food (study III). Data are shown as the mean.
TABLE 3. PK Parameters for Plasma d- Plus l-methylphenidate After Administration of PRC-063 as Intact Capsules or as Capsule
Contents Sprinkled on Different Foods (Study III)
Intact Capsules (n = 29) Apple Sauce (n = 28) Yoghurt (n = 28) Ice Cream (n = 28)
AUC0–24, ng · h/mL,
mean ± SD (CV)
219.97 ± 81.46 (37.03%) 225.03 ± 74.45 (33.09%) 216.61 ± 67.99 (31.39%) 219.44 ± 66.76 (30.42%)
AUC0–t*, ng · h/mL,
mean ± SD (CV)
248.86 ± 99.52 (39.99%) 249.38 ± 87.66 (35.15%) 245.64 ± 84.29 (34.31%) 248.82 ± 88.25 (35.47%)
AUC0–inf, ng · h/mL,
mean ± SD (CV)
255.82 ± 104.90 (41.01%) 254.17 ± 90.81 (35.73%) 252.74 ± 90.27 (35.72%) 258.58 ± 105.33 (40.73%)
Cmax, ng/mL, mean ± SD (CV) 15.74 ± 5.59 (35.48) 17.38 ± 6.07 (34.93%) 15.69 ± 4.72 (30.08%) 16.41 ± 4.63 (28.20%)
Tmax, median (range), h 10.0 (1.0–16.0) 12.0 (1.0–16.0) 11.0 (0.5–16.0) 12.0 (1.0–24.0)
T½ el, mean ± SD, h 4.96 ± 1.15 4.48 ± 1.06 4.99 ± 1.35 4.83 ± 1.62
Residual area†, mean ± SD, % 2.44 ± 2.05 1.74 ± 1.38 2.41 ± 2.16 2.66 ± 4.27
*t = 36 hours.
†36 hours to infinity.
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methylphenidate are believed to translate into prolonged symptom
improvement throughout the day when other shorter-acting products
are wearing off. Indeed, they inform the observed maintenance of
clinical response to PRC-063 through evening hours.21,28
In study III, PK profiles were similar when PRC-063 was ad-
ministered as intact capsules and when capsule contents were
sprinkled on food. The present findings indicate that sprinkling
capsule contents on certain soft foods does not compromise the
PK profile of PRC-063 and is a dosing option that may be useful
for patients who have difficulty swallowing capsules. Patients
should be reminded to swallow the capsule contents when sprin-
kled on food, without chewing, immediately or within 10minutes.
Although the presented data are for d- plus l-methylphenidate
(total methylphenidate), it should be noted that d-methylphenidate
accounted for more than 97.5% of the value of AUC0–t in all 3 stud-
ies. This, together with animal and human studies indicating the rel-
ative inactivity of l- versus d-methylphenidate,29 suggests that the
clinical effects of PRC-063 result primarily from d-methylphenidate.
No unexpected safety trends were detected: the observed
AEs were generally consistent with the established safety profile
of methylphenidate. In study II, only 1 subject was withdrawn be-
cause of an AE that was possibly linked to PRC-063 compared
with 2 subjects for IR methylphenidate. Decreased appetite, head-
ache, dry mouth, and initial insomniawere among the most common
AEs with PRC-063. However, the overall rate of insomnia-related
AEs was 39% for PRC-063, largely as a result of the high rate of ini-
tial insomnia (53%) in study III. This is higher than the rate of 12%
for insomnia-related AEs for IR methylphenidate in study II and
higher than the rate of 6% and 12% for initial insomnia for
PRC-063 in previously reported clinical trials in adults with
ADHD.23 It should be noted that participants in this PK study re-
ceived PRC-063 at a daily dose of 100 mg—the highest available
dose—whereas patients are individually titrated to their optimal
dose. Moreover, the participants were healthy subjects not previ-
ously exposed to stimulant treatment, which may have contributed
to their sleep problems. In addition, subjects in all studies required
overnight stays and slept in bunk beds in an unfamiliar communal
environment, likely contributing to the high rates of insomnia. In-
somnia is a common adverse effect of stimulant treatment,30 and
previous clinical trials in adult patients with ADHD have reported
higher rates of insomnia during treatment with stimulants versus
placebo.23,31 However, evidence suggests that multiple daily dos-
ing may have a greater impact on sleep than long-acting stimulant
treatment32 and that stimulants may improve sleep parameters in
some patients with ADHD.33,34 For these reasons, it is anticipated
that persistence of PRC-063–derived methylphenidate in the
blood until evening would maintain symptom relief without caus-
ing significant sleep problems. Indeed, randomized, double-blind,
placebo-controlled studies in adult ADHD patients have shown no
significant impact of PRC-063 on overall sleep quality.20,23
Concentration versus time curves for plasma methylpheni-
date show considerable between-subject variation in the uptake
of the same dose of methylphenidate, which is typical of methyl-
phenidate formulations.35,36 This confirms the need for individu-
alization of doses. The large number of available dosage strengths
for PRC-063 (25, 35, 45, 55, 70, and 85 mg in the United States;
these same dosage strengths plus 100 mg in Canada) facilitates in-
dividualization of titration and dosing.
Limitations of the presented studies include the use of a
lower daily dose of IR methylphenidate than PRC-063 in studies
I and II, which was because the highest approved daily dose for
IR methylphenidate is only 60 mg.25 However, this difference
was accounted for in the dose-normalized analyses. Inclusion of
participants who smoke a maximum of 25 cigarettes a day may
have affected the results because smoking may induce enzymes
involved in the metabolism of methylphenidate. However, to
counteract this possibility, participants were required to refrain
from smoking for a period before and after morning dosing on
days when blood samples were collected for PK analyses. A fur-
ther limitation is noncollection of a morning PK sample on day
2 in study II, which limits the calculation of steady state to day
3 or later. Moreover, caution should always be used when inter-
preting PK data because they do not always correlate with clinical
effects. Furthermore, the controlled environment of a PK study in
healthy subjects may not reflect real-world conditions for ADHD
patients, where variable timing of dosing and the complex inter-
play between ADHD effects, stimulant effects, and comorbidities
can influence treatment effects. An ongoing study collecting
real-world data on the use of PRC-063 in standard clinical practice
settings (NCT04152629) aims to address this limitation.
CONCLUSIONS
These 3 PK studies provide helpful insights into the clinical
effects of PRC-063. Study I demonstrated equivalent plasmamethyl-
phenidate levels between PRC-063 and TID IR methylphenidate. It
is important to note that the observed higher methylphenidate levels
obtained in the evening with PRC-063 versus TID IR methylpheni-
date point to the extended duration of methylphenidate delivery pro-
vided by PRC-063, which is relevant to patients who require a
long-acting stimulant. No differences in overall exposure to methyl-
phenidate were seen when PRC-063 was taken with a high-fat meal
versus when fasting, confirming that PRC-063 can be taken with or
without food. However, slower uptake after a high-fat meal suggests
that some patients may benefit from taking PRC-063 before break-
fast. Nonetheless, it is prudent to consistently administer PRC-063
with orwithout food tominimize variability in drug uptake and onset
of action. After steady state is reached at day 3, lack of methylpheni-
date accumulation during repeat dosing and a lower fluctuation in-
dex suggest the consistency of this extended-release formulation.
Finally, the similar PK for PRC-063 taken as an intact capsule and
by sprinkling gives patients who have difficulty swallowing capsules
the additional dosing option of sprinkling PRC-063 capsule contents
on certain types of soft foods.
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